COMP <GO>
EWTX vs TVTX // 10Y YIELD & FRED MACRO BETA
Edgewise Therapeutics Inc. (NASDAQ) VS. Travere Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EWTX 4
— TVTX 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: EWTX
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
macro-sensitivity
1.10
LAST: $49.26 (-2.24%) • MKT CAP: $4.75B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. TVTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | TVTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | -13.00% | -18.90 | TVTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | 0.33% | -3.74 | TVTX | /fcf-yield <GO> |
| Operating Margin | -16.20% | -12.80% | -3.40 | TVTX | /operating-margins <GO> |
| Net Profit Margin | 0.00% | -5.20% | +5.20 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 110.50% | -111.60 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.44 | +22.56 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | TVTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 35.8 | +9.90 | EWTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.10 | 1.08 | +0.02 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 18.0x | +7.00 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $4.75B | -$525.1M | TVTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | TVTX REV | EWTX GROSS % | TVTX GROSS % | EWTX FCF | TVTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $535.9M | $490.7M | — | 97.9% | -$144.1M | $15.7M |
| FY 2024 | $444.7M | $233.2M | — | 96.7% | -$110.3M | -$248.0M |
| FY 2023 | $320.2M | $145.2M | — | — | -$91.9M | -$286.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
TVTX // BETA 1.08